{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:56:41Z","timestamp":1772161001620,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1136\/annrheumdis-2013-204575","type":"journal-article","created":{"date-parts":[[2014,1,9]],"date-time":"2014-01-09T06:07:57Z","timestamp":1389247677000},"page":"529-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":275,"title":["Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis"],"prefix":"10.1016","volume":"73","author":[{"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[]},{"given":"C\u00e9cile","family":"Gaujoux-Viala","sequence":"additional","affiliation":[]},{"given":"Jackie L","family":"Nam","sequence":"additional","affiliation":[]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[]},{"given":"Maya","family":"Buch","sequence":"additional","affiliation":[]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2013-204575_bib1","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","author":"Smolen","year":"2014733","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/ard.2008.091926","article-title":"European biologicals registers: methodology, selected results and perspectives","volume":"68","author":"Zink","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological DMARDs\u2014a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/annrheumdis-2013-204588","article-title":"Efficacy of conventional synthetic DMARDs, glucocorticoids and tofacitinib\u2014a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Gaujoux-Viala","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib6","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","article-title":"EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"66","author":"Hoes","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib7","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","author":"Duru","year":"2013721905","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib9","series-title":"Evidence-based medicine: how to practice and teach EBM","author":"Sackett","year":"1997"},{"key":"10.1136\/annrheumdis-2013-204575_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2013-204575_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2013-204575_bib12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib13","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2013-204575_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/rheumatology\/kep325","article-title":"Initiation of rheumatoid arthritis treatments and the risk of serious infections","volume":"49","author":"Grijalva","year":"2010","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2013-204575_bib15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3899\/jrheum.101009","article-title":"Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety","volume":"38","author":"Komano","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204575_bib16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/acr.21666","article-title":"Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis","volume":"64","author":"Sakai","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2013-204575_bib17","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MD.0b013e318211106a","article-title":"TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis","volume":"90","author":"Lane","year":"2011","journal-title":"Medicine"},{"key":"10.1136\/annrheumdis-2013-204575_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/rheumatology\/ker146","article-title":"The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2013-204575_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib21","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2013-204575_bib23","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garcia-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2013-204575_bib25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib26","first-page":"679","article-title":"Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong\u2013the role of TNF blockers in an area of high tuberculosis burden","volume":"28","author":"Tam","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204575_bib27","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","article-title":"Mycobacterial diseases and antitumour necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib29","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/ard.2011.152769","article-title":"Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Galloway","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib30","first-page":"920","article-title":"Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy","volume":"27","author":"Pena-Sagredo","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204575_bib31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/ard.2010.146365","article-title":"The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents","volume":"70","author":"Curtis","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.semarthrit.2012.04.001","article-title":"Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-alpha drugs","volume":"42","author":"Nguyen-Khoa","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib33","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1002\/art.24941","article-title":"Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?","volume":"60","author":"Askling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","article-title":"Cancer in patients with rheumatic diseases exposed to TNF antagonists","volume":"41","author":"Carmona","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","article-title":"Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry","volume":"9","author":"Pallavicini","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1136\/annrheumdis-2013-204575_bib37","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2013-204575_bib38","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2013-204575_bib39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/ard.2009.117762","article-title":"Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry","volume":"69","author":"Mariette","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib41","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2013-204575_bib42","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib43","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"10.1136\/annrheumdis-2013-204575_bib44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/rheumatology\/keq301","article-title":"Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers","volume":"50","author":"Strangfeld","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2013-204575_bib45","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib46","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/pds.3354","article-title":"Association between anti-TNF-alpha therapy and all-cause mortality","volume":"21","author":"Herrinton","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/annrheumdis-2013-204575_bib47","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/art.27660","article-title":"No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Lunt","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib48","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1002\/art.34582","article-title":"Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register","volume":"64","author":"Simard","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2012.05.004","article-title":"Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients","volume":"42","author":"Thyagarajan","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib50","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1136\/annrheumdis-2012-201638","article-title":"Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study","volume":"71","author":"Arkema","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib51","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/ard.2009.111500","article-title":"Demyelinating events in rheumatoid arthritis after drug exposures","volume":"69","author":"Bernatsky","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","article-title":"Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study","volume":"155","author":"Winthrop","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1136\/annrheumdis-2013-204575_bib53","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/art.30654","article-title":"Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis","volume":"64","author":"Ljung","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib55","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.30107","article-title":"The incidence of gastrointestinal perforations among rheumatoid arthritis patients","volume":"63","author":"Curtis","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib56","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/acr.21764","article-title":"Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2013-204575_bib57","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1136\/ard.2011.153536","article-title":"Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Davies","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib58","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/ard.2009.112136","article-title":"Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis","volume":"69","author":"Sokolove","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib60","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/ard.2010.144741","article-title":"The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study","volume":"70","author":"Dixon","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib61","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology"},{"issue":"2","key":"10.1136\/annrheumdis-2013-204575_bib64","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/annrheumdis-2013-204575_bib65","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2013-204575_bib66","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/ard.2009.125526","article-title":"EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib67","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","article-title":"Postmarketing surveillance of the safety and effectiveness of etanercept in Japan","volume":"36","author":"Koike","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204575_bib68","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib69","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/s10165-011-0541-5","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients","volume":"22","author":"Koike","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204575_bib70","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2013-eular.1372","article-title":"Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry\u2013roactemra)","volume":"72","author":"Morel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-204575_bib71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/03009742.2012.762037","article-title":"Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis","volume":"42","author":"Hishitani","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204575_bib72","article-title":"Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry","author":"Horak","year":"2013321451","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2013-204575_bib73","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-204575_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/acr.22056","article-title":"Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the AutoImmunity and Rituximab registry","author":"Godot","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1136\/annrheumdis-2013-204575_bib75","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12325-013-0047-y","article-title":"Tofacitinib for treatment of rheumatoid arthritis","volume":"30","author":"Rakieh","year":"2013","journal-title":"Adv Ther"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724211584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724211584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2013-204575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:31:24Z","timestamp":1737250284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724211584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0003496724211584"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-204575","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-204575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-204577","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}